HopeStage
Study directory

Schizophrenia studies

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

Back to overview
More filters: keywords, city, remote
4505studies shown
Showing 481-492 of 4,505
Behavioral study icon
RecruitingNCT06286202

Cognitive-remediation program or standard rehabilitation for serious mental health conditions

About this title

Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial

Read the official source — NCT06286202
Official study title

Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE): a Community-Based Cognitive Remediation Trial

In Singapore
SchizophreniaBehavioural studyAges 21–60
Countries
Singapore
Sponsor
Singapore Institute of Technology
Behavioral study icon
RecruitingNCT06005766

Group metacognitive skills training for people receiving forensic psychiatric care

About this title

The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care

Read the official source — NCT06005766
Official study title

Does Group-Based Metacognitive Skills Training Reduce Jumping to Conclusions Bias of Patients With Psychotic Disorders in the Context of Forensic Psychiatric Care

In Vaasa
Schizophrenia, DepressionBehavioural studyAges 18+
Countries
Finland
Sponsor
University of Jyvaskyla
Device study icon
Not Yet RecruitingNCT07593456

NST-SPARK Phase 1 STTR (IGNITE)

Official study title

Investigating a Gamified NegatIve-symptom Therapeutic Based on Evidence-based Cognitive Therapy (IGNITE)

This study isn't recruiting yet.

Multiple locations, including Glen Oaks
SchizophreniaDevice studyAges 18–65
Countries
United States
Sponsor
North Shore Therapeutics, Inc.
Other study type icon
RecruitingNCT07387705

On Track for Wellness (OTW) Stepped Wedge Cluster study

Official study title

On Track for Wellness: Stepped-wedge Cluster Randomized Trial of a Fitbit Enhanced Health Intervention for Early Onset Psychosis

In Chicago
SchizophreniaInterventional study
Countries
United States
Sponsor
University of Illinois Chicago
Drug study icon
CompletedNCT00650611

Safety study of ziprasidone in Schizophrenia

Official study title

A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including San Diego
Schizophrenia, BipolarityMedication studyAges 10–17
Countries
United States
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
TerminatedNCT03669640

Effects of RO6889450 (Ralmitaront) in people with Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Official study title

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

This study ended early.

Multiple locations, including Bellflower
SchizophreniaMedication studyAges 18–55
Countries
United States, Japan, Spain, + 1 other
Sponsor
Hoffmann-La Roche
Drug study icon
WithdrawnNCT06878833

Safety study of Long-Acting Oral Risperidone in schizophrenia

Official study title

A Multidose, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

This study was withdrawn before enrollment.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Lyndra Inc.
Drug study icon
CompletedNCT04512066

A study of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in people with an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

What is this study about?

This study evaluated the safety and effectiveness of RO6889450 for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–45
Countries
United States, Japan, Russia, + 1 other
Sponsor
Hoffmann-La Roche
Drug study icon
CompletedNCT01101464

A study to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

Official study title

A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Organon and Co

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.